 Kintara Therapeutics Inc, an oncology-focused, clinical-stage biopharmaceutical company received a Buy rating from Aegis Capital. The analysts noted the biotech firm, which is developing VAL-083 for the treatment of glioblastoma multiforme GBM and REM-001 for the treatment of cutaneous metastatic breast cancer has several catalysts ahead that could lead to company growth. 